Gabriella Ferrandina, MD
Gabriella Ferrandina, MD
Consultant Researcher
Catholic University of the Sacred Heart
Largo A. Gemelli
1
Milan
Italy
20123
Papers:
330
The ratio between type 1 and type 2 tumor-associated macrophages predicts prognosis in patients with locally advanced cervical cancer receiving chemoradiation
Phase III SCORPION trial (ID number: NCT01461850) in epithelial ovarian cancer patients with high tumor load receiving PDS versus NACT: ad interim analysis on peri-operative outcome